# Insulet (PODD) Forecast Calculator

Interactive five-year financial forecast and DCF for Insulet. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/insulet/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 738200000 | -65300000 | 77900000 | 11600000 |
| 2022 | 904400000 | -45000000 | 106900000 | 6800000 |
| 2023 | 1098800000 | -180000000 | 183400000 | 16800000 |
| 2024 | 1305300000 | -3900000 | 100800000 | 4600000 |
| 2025 | 1697100000 | 70100000 | 292900000 | 206300000 |

## Frequently asked questions

### What does Insulet Corporation do?

Insulet Corporation is an innovative medical device company that develops, manufactures, and sells the Omnipod system. This system provides continuous and tubeless automated insulin delivery for people with insulin-requiring diabetes.

### How does Insulet Corporation generate revenue?

Insulet operates a "razor and razorblade" business model, generating recurring revenue through the ongoing sale of disposable Omnipod pods via the pharmacy channel. Its U.S. Omnipod segment accounts for approximately 70% of total revenue, with International Omnipod contributing about 28%.

### What are the key revenue growth assumptions in Insulet's financial model?

The financial model for Insulet Corporation assumes a Revenue_Growth rate of 20% (0.2) for the forecast horizon. This reflects the company's high-growth trajectory, supported by factors like the expansion of its total addressable market.

### What is the purpose of Insulet's equity valuation model?

The model provides a comprehensive equity valuation and scenario analysis framework. Its purpose is to determine if Insulet's high-growth trajectory and operating margin expansion justify its premium market valuation amidst intensifying competition.

### Can I download an Excel financial model for Insulet Corporation?

Yes, an Excel financial model for Insulet Corporation (PODD) is available for download. This model offers a comprehensive framework for equity valuation and scenario analysis, forecasting through FY2030.

### What is Insulet's competitive position in the automated insulin delivery market?

Insulet holds a dominant competitive position as the global leader in tubeless insulin pumps, consistently ranking first in new customer starts. Key competitors include Tandem Diabetes Care, Medtronic, and Beta Bionics.